Literature DB >> 16723497

Mapping residues in the ligand-binding domain of the 5-HT(3) receptor onto d-tubocurarine structure.

Dong Yan1, Julia K Meyer, Michael M White.   

Abstract

The serotonin 5-HT(3) receptor (5-HT(3)R) is a member of the cys-loop ligand-gated ion channel family. We have used the combination of site-directed mutagenesis, homology modeling of the 5-HT(3)R extracellular domain, and ligand docking simulations as a way to map the architecture of the 5-HT(3)R ligand binding domain. Mutation of Phe226 in loop C of the binding site to tyrosine (F226Y) has no effect on the apparent affinity of the competitive antagonist d-tubocurarine (dTC) for the receptor. On the other hand, replacement of Asn128 in loop A of the binding site with alanine (N128A) increases the apparent affinity of dTC by approximately 10-fold. Double-mutant cycle analysis employing a panel of dTC analogs with substitutions at various positions to identify specific points of interactions between the dTC analogs and Asn128 suggests that Asn128 makes a direct interaction with the 2'N of dTC. Molecular modeling of the 5-HT(3)R extracellular domain using the antagonist-bound conformation of the Aplysia californica acetylcholine binding protein as a template followed by ligand docking simulations produces two classes of structures of the 5-HT(3)R/dTC complex; only one of these has the 2'N of dTC positioned at Asn128 and thus is consistent with the data from this study and previously published data. The use of the rigid dTC analogs as "molecular rulers" in conjunction with double-mutant cycle analysis of mutant receptors can allow the spatial mapping of the position of various residues in the ligand-binding site.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723497     DOI: 10.1124/mol.106.024075

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

1.  Mapping spatial relationships between residues in the ligand-binding domain of the 5-HT3 receptor using a molecular ruler.

Authors:  Heather L Nyce; Spencer T Stober; Cameron F Abrams; Michael M White
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

2.  Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT3AB receptors.

Authors:  A J Thompson; K L Price; S C R Lummis
Journal:  J Physiol       Date:  2011-06-27       Impact factor: 5.182

3.  Unbalanced Peptidergic Inhibition in Superficial Neocortex Underlies Spike and Wave Seizure Activity.

Authors:  S Hall; M Hunt; A Simon; L G Cunnington; L M Carracedo; I S Schofield; R Forsyth; R D Traub; M A Whittington
Journal:  J Neurosci       Date:  2015-06-24       Impact factor: 6.167

Review 4.  Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.

Authors:  Tina K Machu
Journal:  Pharmacol Ther       Date:  2011-02-26       Impact factor: 12.310

5.  A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors.

Authors:  Marijke Brams; Anshul Pandya; Dmitry Kuzmin; René van Elk; Liz Krijnen; Jerrel L Yakel; Victor Tsetlin; August B Smit; Chris Ulens
Journal:  PLoS Biol       Date:  2011-03-29       Impact factor: 8.029

6.  Does Epileptiform Activity Represent a Failure of Neuromodulation to Control Central Pattern Generator-Like Neocortical Behavior?

Authors:  Roger D Traub; Miles A Whittington; Stephen P Hall
Journal:  Front Neural Circuits       Date:  2017-10-18       Impact factor: 3.492

7.  Structural basis of ligand recognition in 5-HT3 receptors.

Authors:  Divya Kesters; Andrew J Thompson; Marijke Brams; René van Elk; Radovan Spurny; Matthis Geitmann; Jose M Villalgordo; Albert Guskov; U Helena Danielson; Sarah C R Lummis; August B Smit; Chris Ulens
Journal:  EMBO Rep       Date:  2012-11-30       Impact factor: 8.807

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.